OBJECTIVE: It is not known how frequently abnormal albumin excretion occurs in the initial years after the onset of type 2 diabetes and to what extent its occurrence is related to the severity of diabetes. We have used a prospective cohort study to examine this. RESEARCH DESIGN AND METHODS: A total of 782 participants from the Strong Heart Study who had normal glucose tolerance and normal albumin excretion (albumin-to-creatinine ratio <30 mg albumin/g creatinine) at baseline were assessed for diabetes and abnormal albumin excretion at a follow-up visit (interval 3.91 +/- 0.95 years, mean +/- SD). Logistic regression models were used to examine the associations. RESULTS: Abnormal albumin excretion was detected in 52 (6.6%) and diabetes was determined to be present in 105 (13.4%) of the participants at the follow-up visit. In univariate analyses, abnormal albumin excretion was statistically significantly related to the baseline albumin-to-creatinine ratio, diastolic blood pressure, fasting insulin, and extent of American Indian heritage. Abnormal albumin excretion was much more prevalent in those with recent onset diabetes at the follow-up visit (18 vs. 5%, P < 0.001). In a logistic regression analysis, abnormal albumin excretion and diabetes remained strongly related (odds ratio 3.45, P < 0.001), and associations of abnormal albumin excretion with baseline albumin-to-creatinine ratio, blood pressure, and American Indian heritage also remained significant in a separate logistic regression analysis, including only those who developed diabetes. There was a strong association between abnormal albumin excretion and fasting glucose levels (<0.01) at the follow-up visit. CONCLUSIONS: These data suggest that an appreciable percentage of individuals develop abnormal albumin excretion within the first few years after the onset of type 2 diabetes. Also, the severity of diabetes at onset appears to be a key risk factor for the early development of abnormal albumin excretion.
OBJECTIVE: It is not known how frequently abnormal albumin excretion occurs in the initial years after the onset of type 2 diabetes and to what extent its occurrence is related to the severity of diabetes. We have used a prospective cohort study to examine this. RESEARCH DESIGN AND METHODS: A total of 782 participants from the Strong Heart Study who had normal glucose tolerance and normal albumin excretion (albumin-to-creatinine ratio <30 mg albumin/g creatinine) at baseline were assessed for diabetes and abnormal albumin excretion at a follow-up visit (interval 3.91 +/- 0.95 years, mean +/- SD). Logistic regression models were used to examine the associations. RESULTS: Abnormal albumin excretion was detected in 52 (6.6%) and diabetes was determined to be present in 105 (13.4%) of the participants at the follow-up visit. In univariate analyses, abnormal albumin excretion was statistically significantly related to the baseline albumin-to-creatinine ratio, diastolic blood pressure, fasting insulin, and extent of American Indian heritage. Abnormal albumin excretion was much more prevalent in those with recent onset diabetes at the follow-up visit (18 vs. 5%, P < 0.001). In a logistic regression analysis, abnormal albumin excretion and diabetes remained strongly related (odds ratio 3.45, P < 0.001), and associations of abnormal albumin excretion with baseline albumin-to-creatinine ratio, blood pressure, and American Indian heritage also remained significant in a separate logistic regression analysis, including only those who developed diabetes. There was a strong association between abnormal albumin excretion and fasting glucose levels (<0.01) at the follow-up visit. CONCLUSIONS: These data suggest that an appreciable percentage of individuals develop abnormal albumin excretion within the first few years after the onset of type 2 diabetes. Also, the severity of diabetes at onset appears to be a key risk factor for the early development of abnormal albumin excretion.
Authors: Yun Zhu; Jingyun Yang; Shengxu Li; Shelley A Cole; Karin Haack; Jason G Umans; Nora Franceschini; Barbara V Howard; Elisa T Lee; Jinying Zhao Journal: J Hypertens Date: 2014-05 Impact factor: 4.844
Authors: Stacey E Jolly; Carolyn J Noonan; Yvette D Roubideaux; Jack H Goldberg; Sven O E Ebbesson; Jason G Umans; Barbara V Howard Journal: Nephron Clin Pract Date: 2010-04-21
Authors: Stacey E Jolly; Suying Li; Shu-Cheng Chen; Andrew S Narva; Claudine T Jurkovitz; Keith C Norris; Michael G Shlipak Journal: Am J Nephrol Date: 2008-11-14 Impact factor: 3.754
Authors: James Michael Zacharias; T Kue Young; Natalie D Riediger; Joanne Roulette; Sharon G Bruce Journal: BMC Public Health Date: 2012-04-20 Impact factor: 3.295
Authors: Timothy C Nichols; Elizabeth P Merricks; Dwight A Bellinger; Robin A Raymer; Jing Yu; Diana Lam; Gary G Koch; Walker H Busby; David R Clemmons Journal: PLoS One Date: 2015-07-06 Impact factor: 3.240